ABO blood group-incompatible(ABOi)transplantation has been developed to overcome the serious problem of donor organ shortage.However,antibody-mediated rejection(ABMR)remains as the main limitation to successful ABOi t...ABO blood group-incompatible(ABOi)transplantation has been developed to overcome the serious problem of donor organ shortage.However,antibody-mediated rejection(ABMR)remains as the main limitation to successful ABOi transplantation.Introduction of desensitization treatment improved the outcomes of ABOi transplantation by suppressing ABMR;however,this strong,nonspecific immunosuppression also increases infectious complications.Recently,chimeric antigen receptor regulatory T cells(CAR Tregs)were developed to improve the antigen specificity,viability,and suppressive activity of Tregs.C4d deposition is a marker of ABMR and is also found in most ABOi allograft tissues.Based on these findings,we developed anti-C4d CAR Tregs to suppress ABMR in ABOi allografts.展开更多
基金This study was supported by a grant from the Ministry of Health and Welfare(No.HI18C0532),Republic of Korea
文摘ABO blood group-incompatible(ABOi)transplantation has been developed to overcome the serious problem of donor organ shortage.However,antibody-mediated rejection(ABMR)remains as the main limitation to successful ABOi transplantation.Introduction of desensitization treatment improved the outcomes of ABOi transplantation by suppressing ABMR;however,this strong,nonspecific immunosuppression also increases infectious complications.Recently,chimeric antigen receptor regulatory T cells(CAR Tregs)were developed to improve the antigen specificity,viability,and suppressive activity of Tregs.C4d deposition is a marker of ABMR and is also found in most ABOi allograft tissues.Based on these findings,we developed anti-C4d CAR Tregs to suppress ABMR in ABOi allografts.
